JNJ Stock Hits 52-Week High on Strong Revenue Growth

Johnson & Johnson's stock has been trading near its 52-week high after experiencing a significant rise of 55% in value. This growth can be attributed to strong revenue and promising sales of key products such as DARZALEX and TREMFYA. The company recently raised its full-year guidance, indicating continued expansion in these areas.

However, despite this positive news, analysts advise caution due to the stock's high valuation and ongoing litigation issues. They recommend holding onto the stock for now and waiting for clearer catalysts or a price pullback before making further investments.